Ocugen, Inc.
Ocugen is a biotechnology company developing gene therapies and other treatments for vision disorders, including inherited retinal diseases and geographic atrophy. Its modifier gene therapy programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy, and OCU410ST for Stargardt disease. Ocugen also develops OCU200, a biologic candidate for diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration; a regenerative cell therapy platform that includes NeoCart for knee cartilage injuries in adults; and an inhaled vaccine platform with candidates for COVID-19, seasonal flu, and a combination of the two. Ocugen’s business centers on developing product candidates through clinical trials and pursuing their potential commercialization. It also has licensing and development arrangements and a partnership with CanSino Biologics for its modifier gene therapy platform. Ocugen is headquartered in Malvern, Pennsylvania.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $OCGN in the last 30 days.
See all $OCGN insider activity →Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN · Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Aust
Ocugen (OCGN) licensed OCU400, a gene therapy for retinitis pigmentosa, to Celairis for Asia-Pacific. Deal includes up to $7.1M in payments, royalties, and profit-sharing. Celairis will commercialize the therapy, with Ocugen manufacturing. Phase 3 trial results expected in Q1 2027.
Ocugen reported Q3 2026 progress, with all three late-stage gene therapy programs in phase III. OCU400 for retinitis pigmentosa completed enrollment, with top-line data expected in Q1 2027. The company secured a $4M upfront license deal for the Middle East and North Africa. Financials showed $84.6M in cash and a $0.01 net loss per share, down from $0.07 in 2025. Ocugen aims to file three BLAs by 2028.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning OCGN (Ocugen, Inc.). Coverage has skewed bullish: 4 bullish, 7 neutral, and 3 bearish.
Recent OCGN coverage spans financial news, corporate actions and earnings.
The deal adds near‑term cash and potential milestone upside, but the therapy remains unapproved and revenue is far in the future.
The deal adds a new revenue stream and expands Ocugen's market reach, likely supporting the stock modestly.
Near-term catalyst is the Phase III readout timeline (Q1 2027) and incremental commercial/regulatory progress (Roots license, Bahamas access pathway).
Quarterly loss and cash runway suggest near‑term downside, but positive trial progress may support upside.
The deal adds significant future revenue potential and could boost the stock.
AlphAI scores every news story that mentions OCGN with an AI model for sentiment and relevance, and aggregates insider trades from Ocugen, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN · Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Aust
Ocugen (OCGN) licensed OCU400, a gene therapy for retinitis pigmentosa, to Celairis for Asia-Pacific. Deal includes up to $7.1M in payments, royalties, and profit-sharing. Celairis will commercialize the therapy, with Ocugen manufacturing. Phase 3 trial results expected in Q1 2027.
Ocugen reported Q3 2026 progress, with all three late-stage gene therapy programs in phase III. OCU400 for retinitis pigmentosa completed enrollment, with top-line data expected in Q1 2027. The company secured a $4M upfront license deal for the Middle East and North Africa. Financials showed $84.6M in cash and a $0.01 net loss per share, down from $0.07 in 2025. Ocugen aims to file three BLAs by 2028.
Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ocugen Provides Business Update with Third Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET · Received Provisional Approval and Priority Designation for OCU400 in The Bahamas o Executed agreement with local partner Global Alliance for
Ocugen (OCGN) licensed MENA rights for OCU400 to Roots Pharmaceutical, receiving up to $259M in milestones and a 22% royalty. Roots will handle regulatory filings and commercialization, while Ocugen supplies the product. The agreement aims to expand OCU400's market reach.
Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa October 14, 2026 · Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocuge
Ocugen Inc. (OCGN) has set up a European affiliate in Amsterdam, appointing Jolanda Crombach to lead it. The move supports regulatory filings and commercialization of three gene therapies for retinal diseases, with trial results expected in 2027-2028. Crombach brings experience from Moderna, MSD, and Pfizer.
The Third Circuit Court of Appeals overturned its 'Oran-Burlington rule,' which used stock price movements to determine materiality in securities fraud cases. The court now adopts the Supreme Court's 'total mix' standard. Ocugen, a pharmaceutical company, was involved in the case due to alleged misstatements in its financials related to a collaboration agreement with CanSinoBIO. The decision may impact securities fraud litigation in the Third Circuit.
Ocugen, Inc. (OCGN) appointed Jolanda Crombach as General Manager of its new European affiliate in Amsterdam to support its three Phase 3 gene therapy programs, aligning with its late-stage ophthalmology pipeline and anticipated EU submissions.
Ocugen, Inc. (OCGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 5, 2026, Ocugen, Inc. (the “Company”) reconvened its Special Meeting of Stockholders (the “Special Meeting”) virtually, which had been adjourned on September 21, 2026 solely with respect to the proposal to
